Supplement 1. Methods

Data sources

Sources of data on vaccination status, SARS-CoV-2 testing, identification of variants, covariates included in the analyses and data linkage methods have been described previously. Data on all PCR-tests were extracted on 23/11/2021 from week 37 2021 for 12-15-year-olds and week 32 2021 for 16-17-year-olds. For 18-39-year-olds, this was from week 21 2021 if no sequencing or S-Gene Target Failure (SGTF) data available or from week 19 2021 if the sample was sequenced as Delta or as a non-SGTF. For 40-64-year-olds, this was from week 21 2021 if no sequencing or SGTF data or from week 15 2021 for cases if sequenced as Delta or as a non-SGTF. Those vaccinated before the above periods were not included except for age 40-64 where only those vaccinated before week 5 2021 were not included. These restrictions were done to reflect the time that vaccination was a general recommendation in these age groups. Tests performed >10 days after symptom-onset were excluded. Individuals who had previously tested positive (PCR or antibody) prior to the sample date were also excluded from the analysis. A maximum of 4 negative tests could be included per person as long as they were more than 7 days apart and were not after a positive test or within 3 weeks before a positive test. The vast majority only contributed a single negative test.

Testing data and linkage to the Emergency Care Dataset, as well as inclusion and exclusion factors for analysis has been described previously.² Emergency care hospitalisation data were extracted on 22/11/2021 with cases and controls included if tested by 4/11/2021 to allow time for hospitalisation in cases which is defined as within 14 days of a positive test.

Statistical analysis

We have previously reported the methodology for test-negative case-control analysis.¹ Analysis was done by logistic regression with the PCR-test result as the dependent variable and vaccination status included as an independent variable. Vaccine effectiveness was defined as 1- odds of vaccination in cases/odds of vaccination in controls, with vaccination stratified by interval after each dose. Similar

analyses were performed for hospitalisations with all cases included and cases defined as those admitted. Vaccine effectiveness was adjusted in logistic regression models for age (5 year bands), sex, index of multiple deprivation (quintile), ethnic group, geographic region (NHS region), period (calendar week of onset), health and social care worker status (adults), clinical risk group status (a separate flag for those aged over and under 16), clinically extremely vulnerable (if aged 16 and above)), and severely immunosuppressed (adults). For children age was defined as at 31 August 2021 whereas for adults this was age at 31 March 2021.

Supplement 2. Total number of positive and negative PCR-confirmed SARS-CoV-2 test results in individuals tested for SARS-CoV-2 for grouped ages 12-

15, 16-17, 18-39 and 40-64 in England. Children aged 12-15 years have yet to receive their second dose of vaccine in England

	Age group			12-15	i					16-17			
		Overall Positive		re	Negative		Overall		Positive		Negative		
		n	%	n	%	n	%	n	%	n	%	n	%
	Test Result	404,744	100.0	214,920	100.0	189,824	100.0	138,273	100.0	65,059	100.0	73,214	100.0
	Unvaccinated	359,359	88.8	191,026	88.9	168,333	88.7	68,318	49.4	39,168	60.2	29,150	39.8
	Dose 1: day 0-3	9,136	2.3	6083	2.8	3053	1.6	2,551	1.8	1638	2.5	913	1.2
	Dose 1: day 4-6	7,388	1.8	5,048	2.3	2,340	1.2	2,888	2.1	1,644	2.5	1,244	1.7
	Dose 1: day 7-9	6,582	1.6	4,495	2.1	2087	1.1	4,006	2.9	2,034	3.1	1972	2.7
	Dose 1: day 10-13	5,580	1.4	2789	1.3	2,791	1.5	4,708	3.4	1582	2.4	3,126	4.3
	Dose 1: 2 weeks	5,283	1.3	1571	0.7	3,712	2.0	6,766	4.9	1343	2.1	5,423	7.4
	Dose 1: 3 weeks	3,916	1.0	1,195	0.6	2,721	1.4	6,492	4.7	1,187	1.8	5,305	7.2
Vaccination	Dose 1: 4 weeks	3,195	0.8	1,090	0.5	2,105	1.1	6,866	5.0	1,473	2.3	5,393	7.4
Status and intervals	Dose 1: 5 weeks	2,264	0.6	826	0.4	1,438	0.8	6,670	4.8	1,770	2.7	4,900	6.7
after vaccine	Dose 1: 6-7 weeks	1,966	0.5	768	0.4	1,198	0.6	11,252	8.1	4,491	6.9	6,761	9.2
	Dose 1: 8-9 weeks	75	0.0	29	0.0	46	0.0	8,195	5.9	4,315	6.6	3,880	5.3
	Dose 1: 10-11 weeks	-	-	-	-	-	-	5,962	4.3	3,089	4.7	2,873	3.9
	Dose 1: 12+ weeks	-	-	-	-	-	-	2,073	1.5	1,016	1.6	1,057	1.4
	Dose 2: 0-3 days	-	-	-	-	-	-	345	0.2	157	0.2	188	0.3
	Dose 2: 4-6 days	-	-	-	-	-	-	196	0.1	65	0.1	131	0.2
	Dose 2: 1 week	-	-	-	-	-	-	321	0.2	34	0.1	287	0.4
	Dose 2: 2-9 weeks	-	-	-	-	-	-	664	0.5	53	0.1	611	0.8


	Age Group			18-39						40-6	4		
		Overall	Overall		⁄e	Negative		Overall		Positive		Negative	
		n	%	n	%	n	%	n	%	n	%	n	%
	Test Result	1,502,406	100.0	569,421	100.0	932,985	100.0	234,711	100.0	90,900	100.0	143,811	100.0
	Unvaccinated	649,162	43.2	314,215	55.2	334,947	35.9	145,318	61.9	70,752	77.8	74,566	51.8
	Dose 1: day 0-3	20,995	1.4	10,424	1.8	10,571	1.1	1,128	0.5	454	0.5	674	0.5
	Dose 1: day 4-6	20,370	1.4	10388	1.8	9,982	1.1	882	0.4	360	0.4	522	0.4
	Dose 1: day 7-9	23,215	1.5	11,943	2.1	11,272	1.2	995	0.4	430	0.5	565	0.4
	Dose 1: day 10-13	28,390	1.9	11,780	2.1	16,610	1.8	1,276	0.5	440	0.5	836	0.6
	Dose 1: 2 weeks	46,081	3.1	14,751	2.6	31,330	3.4	2,171	0.9	615	0.7	1,556	1.1
	Dose 1: 3 weeks	50,686	3.4	18,038	3.2	32,648	3.5	2,212	0.9	710	0.8	1,502	1.0
Vaccination	Dose 1: 4 weeks	54,689	3.6	21,048	3.7	33,641	3.6	2,408	1.0	807	0.9	1,601	1.1
Status and intervals	Dose 1: 5 weeks	56,842	3.8	23300	4.1	33542	3.6	2,849	1.2	951	1.0	1898	1.3
after vaccine	Dose 1: 6-7 weeks	112,281	7.5	48897	8.6	63,384	6.8	8,014	3.4	2492	2.7	5,522	3.8
	Dose 1: 8-9 weeks	48,574	3.2	21690	3.8	26,884	2.9	6,361	2.7	1884	2.1	4,477	3.1
	Dose 1: 10-11 weeks	18,696	1.2	7,688	1.4	11,008	1.2	3,158	1.3	967	1.1	2,191	1.5
	Dose 1: 12+ weeks	28,230	1.9	10,448	1.8	17,782	1.9	5,424	2.3	2,166	2.4	3,258	2.3
	Dose 2: 0-3 days	24,470	1.6	9,840	1.7	14,630	1.6	2,375	1.0	681	0.7	1,694	1.2
	Dose 2: 4-6 days	16,797	1.1	5169	0.9	11628	1.2	1,724	0.7	421	0.5	1303	0.9
	Dose 2: 1 week	33,438	2.2	3,204	0.6	30,234	3.2	3,546	1.5	342	0.4	3,204	2.2
	Dose 2: 2-9 weeks	269,490	17.9	26,598	4.7	242,892	26.0	44,870	19.1	6,428	7.1	38,442	26.7

Supplement 3. Descriptive characteristics of positive and negative PCR-confirmed SARS-CoV-2 test results among adolescents aged 12-17 years after one and two doses of BNT162b2 (Comirnaty, Pfizer-BioNTech in England. Children aged 12-15 years have yet to receive their second dose of vaccine in England.

		Overall		Positiv	re	Negative		
		n	%	n	%	n	%	
	Test Result	543,017	100.0	279,979	51.6	263,038	48.4	
	Unvaccinated	427,677	78.8	230,194	42.4	197,483	36.4	
	Dose 1: day 0-3	11,687	2.2	7,721	1.4	3,966	0.7	
	Dose 1: day 4-6	10,276	1.9	6,692	1.2	3,584	0.7	
Vaccination	Dose 1: day 7-9	10,588	1.9	6,529	1.2	4,059	0.7	
Status and intervals	Dose 1: day 10-13	10,288	1.9	4,371	0.8	5,917	1.1	
after	Dose 1: 2+ weeks	70,975	13.1	24,163	4.4	46,812	8.6	
vaccine	Dose 2: day 0-3	345	0.1	157	0.0	188	0.0	
	Dose 2: day 4-6	196	0.0	65	0.0	131	0.0	
	Dose 2: day 7-13	321	0.1	34	0.0	287	0.1	
	Dose 2: 2+ weeks	664	0.1	53	0.0	611	0.1	
	12	99,273	18.3	52,579	18.8	46,694	17.8	
	13	102,785	18.9	54,433	19.4	48,352	18.4	
Ago (voors)	14	101,432	18.7	53,451	19.1	47,981	18.2	
Age (years)	15	101,254	18.6	54,457	19.5	46,797	17.8	
	16	69,174	12.7	33,562	12.0	35,612	13.5	
	17	69,099	12.7	31,497	11.2	37,602	14.3	
	Female	274,867	50.6	142,898	51.0	131,969	50.2	
Gender	Male	267,357	49.2	136,704	48.8	130,653	49.7	
	Missing	793	0.1	377	0.1	416	0.2	
	African	7,298	1.3	3,925	1.4	3,373	1.3	
	Another Asian background	6,765	1.2	3,541	1.3	3,224	1.2	
	Another Black background	890	0.2	461	0.2	429	0.2	
	Another ethnic background	3,024	0.6	1,476	0.5	1,548	0.6	
	Arab	2,218	0.4	1,140	0.4	1,078	0.4	
	Bangladeshi	4,497	0.8	2,203	0.8	2,294	0.9	
Ethnicity	Caribbean	2,307	0.4	1,173	0.4	1,134	0.4	
Lumency	Chinese	2,867	0.5	1,474	0.5	1,393	0.5	
	Indian	14,655	2.7	7,280	2.6	7,375	2.8	
	Mixed or multiple ethnic	,		ŕ				
	groups	23,853	4.4	11,945	4.3	11,908	4.5	
	Pakistani	13,371	2.5	5,998	2.1	7,373	2.8	
	Prefer not to say	15,219	2.8	7,440	2.7	7,779	3.0	
	White	446,053	82.1	231,923	82.8	214,130	81.4	

		Overall		Positiv	re	Negative		
		n	%	n	%	n	%	
	East of England	70,215	12.9	36,168	12.9	34,047	12.9	
	London	47,297	8.7	22,961	8.2	24,336	9.3	
	Midlands	110,649	20.4	57,529	20.5	53,120	20.2	
NHS Region	North East	84,866	15.6	44,581	15.9	40,285	15.3	
NH3 Region	North West	67,914	12.5	33,209	11.9	34,705	13.2	
	South East	94,900	17.5	50,323	18.0	44,577	16.9	
	South West	67,174	12.4	35,206	12.6	31,968	12.2	
	Missing	2	0.0	2	0.0	-	-	
	1	94,736	17.4	46,073	16.5	48,663	18.5	
	2	93,331	17.2	47,434	16.9	45,897	17.4	
IMD Ovintiles	3	105,171	19.4	55,082	19.7	50,089	19.0	
IMD Quintiles	4	115,589	21.3	60,907	21.8	54,682	20.8	
	5	133,494	24.6	70,122	25.0	63,372	24.1	
	Missing	696	0.1	361	0.1	335	0.1	
Vaccine priority	At risk	100,915	18.6	46,780	16.7	54,135	20.6	
groups	CEV	265	0.05	112	0.04	153	0.05	

Supplement 4. Weekly incidence of COVID-19 cases per 100,000 population from week 23 2021, in secondary age cohorts (Year 7 to 11) and sixth form age cohorts (Year 12 to Year 13) with dose 1 vaccine uptake in 12-15-year-olds and in 16-17-year-olds.



Graph taken from UKHSA Weekly Influenza and COVID-19 Surveillance graphs ³

Incidence definition: School age cohorts are calculated based on academic year birth cohorts. Those born between 01/09/2004 - 31/08/2005 are included in the year 12 school group and those born between 01/09/2003 - 31/08/2004 are included in the year 13 school group. Case rate denominators are sourced from ONS 2020 mid-year estimates.

Vaccine coverage definition: From Week 42 the ages are calculated based on age as of 31 August 2021. The under 50 age group includes all those aged under 50 including those born after the 31 August 2021 (denominator). Those whose date of birth is after the 31 August 2021, have an age of zero and are included in the denominator. Only vaccinations recorded as given to persons aged greater or equal to 1 have been included (numerator). Both numerators and denominators are sourced from the NIMS and exclude deaths. All data presented are for vaccinations within the living population on the date of extraction and therefore removes both formal and informal registered deaths in the numerator and denominator for the purposes of calculating vaccine uptake.

Supplement 5. Vaccine effectiveness with 95% confidence intervals against symptomatic, PCR-confirmed COVID-19 among adolescents and adults after one and two doses of BNT162b2 (Comirnaty, Pfizer-BioNTech) in England. Children aged 12-15 years have yet to receive their second dose of vaccine in England

Age group	12-15	16-17	18-39	40-64
Interval after vaccine	VE	VE	VE	VE
Dose 1: day 0-3	-27.8 (-33.7 to -22.2)	-16.2 (-26.7 to -6.7)	-9.9 (-13.2 to -6.7)	11.9 (-0.7 to 23)
Dose 1: day 4-6	-30.4 (-37.2 to -23.9)	3.9 (-3.9 to 11.2)	-4.5 (-7.7 to -1.4)	10.9 (-3.5 to 23.3)
Dose 1: day 7-9	-26.4 (-33.3 to -19.7)	23.1 (17.7 to 28.1)	-0.7 (-3.5 to 2.1)	-1.9 (-17.4 to 11.5)
Dose 1: day 10-13	41.4 (38.1 to 44.5)	58.8 (56 to 61.4)	38 (36.4 to 39.5)	37.9 (29.6 to 45.2)
Dose 1: 2 weeks	75.4 (73.9 to 76.9)	75.9 (74.3 to 77.4)	63 (62.2 to 63.8)	54.5 (49.7 to 58.8)
Dose 1: 3 weeks	73.1 (71.2 to 75)	70.1 (68 to 72.1)	60 (59.2 to 60.8)	50.8 (45.9 to 55.3)
Dose 1: 4 weeks	65.7 (63 to 68.2)	60.8 (58.2 to 63.2)	56.8 (56 to 57.6)	47.5 (42.5 to 52)
Dose 1: 5 weeks	58.3 (54.5 to 61.9)	54.9 (52 to 57.5)	54.2 (53.4 to 55.1)	48.9 (44.5 to 52.9)
Dose 1: 6-7 weeks	52.1 (47.4 to 56.4)	42.6 (39.8 to 45.2)	52.4 (51.7 to 53)	45.3 (42.3 to 48.2)
Dose 1: 8-9 weeks	46.8 (14.9 to 66.7)	34.3 (30.7 to 37.7)	46.5 (45.4 to 47.5)	38.4 (34.3 to 42.2)
Dose 1: 10-11 weeks	-	34.3 (30 to 38.3)	41.4 (39.6 to 43.2)	36 (30 to 41.5)
Dose 1: 12+ weeks	-	37.4 (30.8 to 43.3)	39.5 (37.9 to 41)	53 (50.2 to 55.6)
Dose 2: 0-3 days	-	45.1 (31.9 to 55.8)	54.3 (53 to 55.5)	50.3 (45.2 to 55.1)
Dose 2: 4-6 days	-	68.9 (57.9 to 77)	68.8 (67.7 to 69.9)	62.8 (58 to 67)
Dose 2: 1 week	-	92.9 (89.9 to 95.1)	92.2 (91.9 to 92.5)	87.1 (85.5 to 88.5)
Dose 2: 2-9 weeks	-	94.6 (92.8 to 95.9)	88.7 (88.5 to 88.8)	84.1 (83.6 to 84.5)

Supplement 6. Vaccine effectiveness and 95% confidence intervals against hospitalisation following PCR-confirmed COVID-19 among adolescents aged 16-17 with one dose of Comirnaty (PF) in England

		Ove	Overall		sitive	Negative		VE
		n	%	n	%	n	%	
	Test Result	65,187	100.0	88	100.0	64,999	100.0	
	Unvaccinated	26,976	41.4	70	79.5	26,826	41.3	-
Vaccination	day 0-3	897	1.4	2	2.3	893	1.4	34.7 (-170.8 to 84.3)
status and interval	day 4-6	1,223	1.9	3	3.4	1,217	1.9	0.3 (-225.2 to 69.4)
after dose	day 7-9	1,956	3.0	5	5.7	1945	3.0	-16.3 (-202.2 to 55.2)
1	day 10-13	3,083	4.7	1	1.1	3,081	4.7	82.2 (-31.8 to 97.6)
	2 weeks +	31,052	47.6	7	8.0	31,037	47.7	84.5 (64.6 to 93.2)

References

- 1. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. *BMJ* 2021; **373**: n1088.
- 2. Andrews N, Stowe J, Kirsebom F, Gower C, Ramsay M, Bernal JL. Effectiveness of BNT162b2 (Comirnaty, Pfizer-BioNTech) COVID-19 booster vaccine against covid-19 related symptoms in England: test negative case-control study. *medRxiv* 2021: 2021.11.15.21266341.
- 3. UKHSA. Weekly Influenza and COVID-19 Surveillance graphs. 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1035958/Weekly_COVID-19_and_Influenza_Surveillance_Graphs_w47.pdf (accessed 12th December 2021).